Results and Impact of the Follow-Up of the NeoALTTO Trial
Carlos L. Arteaga, MD, discusses the results and impact of the four-year follow-up analysis of the NeoALTTO trial, which analyzed patients with HER2-positive breast cancer.
Clinical Pearls
Carlos L. Arteaga, MD, professor of medicine and cancer biology, Vanderbilt-Ingram Cancer Center, discusses the results and impact of the four-year follow-up analysis of the NeoALTTO trial, which analyzed patients with HER2-positive breast cancer.
- The NeoALTTO trial set out to determine whether the higher pathologic complete response (pCR) rate achieved with lapatinib plus trastuzumab translated into better overall survival or event-free survival
- The hazard for event-free survival was 65%-70% lower for patients who achieved pCR than for those who did not
- This trial is important because the FDA now allows for the approval of novel therapies following testing in the adjuvant setting
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
